Distinct mechanisms of action of tumor... [Semin Arthritis Rheum. 2005] - PubMed

Related citations

Review Switching tumor necrosis factor inhibitors: an opinion. [Nat Clin Pract Rheumatol. 2006]
Review Switching tumor necrosis factor inhibitors: an opinion.
Keystone EC. Nat Clin Pract Rheumatol. 2006 Nov; 2(11):576-7.
Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. [Arthritis Rheum. 2006]
Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis.
Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, Bathon JM. Arthritis Rheum. 2006 Apr 15; 55(2):333-7.
Review TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries. [Bull NYU Hosp Jt Dis. 2007]
Review TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
Nasir A, Greenberg JD. Bull NYU Hosp Jt Dis. 2007; 65(3):178-81.
Review What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis? [Semin Arthritis Rheum. 2005]
Review What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis?
Balandraud N, Roudier J, Roudier C. Semin Arthritis Rheum. 2005 Apr; 34(5 Suppl1):31-3.
Review Health economics: implications for novel antirheumatic therapies. [Ann Rheum Dis. 2005]
Review Health economics: implications for novel antirheumatic therapies.
Kavanaugh A. Ann Rheum Dis. 2005 Nov; 64 Suppl 4:iv65-9.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Distinct mechanisms of action of tumor necrosis factor antagonists: what are the...
Distinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications?
Semin Arthritis Rheum. 2005 Apr ;34(5 Suppl1):1-2.

PubMed
Systematic targeted mutagenesis of Brucella melitensis 16M reveals a major role ...
Systematic targeted mutagenesis of Brucella melitensis 16M reveals a major role for GntR regulators in the control of virulence.
Infect Immun. 2005 Sep ;73(9):5578-86.

PubMed
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin...
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang.
Clin Cancer Res. 2007 Jan 15 ;13(2 Pt 2):733s-740s.

PubMed
TMS evidence for the involvement of the right occipital face area in early face ...
TMS evidence for the involvement of the right occipital face area in early face processing.
Curr Biol. 2007 Sep 18 ;17(18):1568-73. Epub 2007 Aug 30 .

PubMed
MSKs are required for the transcription of the nuclear orphan receptors Nur77, N...
MSKs are required for the transcription of the nuclear orphan receptors Nur77, Nurr1 and Nor1 downstream of MAPK signalling.
Biochem J. 2005 Sep 15 ;390(Pt 3):749-59.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Distinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications?

Source

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Related citations

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information